Prostate cancer (PCa) is the most common male cancer in many countries. The 5-
year survival rates for PCa are rising, with this thought to reflect improvements in
early detection via prostate-specific antigen (PSA) testing and improved outcomes
from treatment options. However, there are also risks associated with PSA testing,
such as misdiagnosis and harmful side-effects from various treatments that may
outweigh any potential benefits, especially for older men.
Available at: http://works.bepress.com/justin_keogh/61/